IPO4

Summary

IPO4 (importin 4, HGNC:19426) is a protein-coding gene on chromosome 14q12, encoding Importin-4 (Q8TEX9). Nuclear transport receptor that mediates nuclear import of proteins, such as histones, RPS3A, TNP2 and VDR.

Enables nuclear import signal receptor activity and nuclear localization sequence binding activity. Involved in protein import into nucleus. Located in chromatin. Part of protein-containing complex.

Source: NCBI Gene 79711 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 289 total
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_024658

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:19426
Approved symbol	IPO4
Name	importin 4
Location	14q12
Locus type	gene with protein product
Status	Approved
Aliases	Imp4, FLJ23338
Ensembl gene	ENSG00000196497
Ensembl biotype	protein_coding
Entrez	79711

Gene structure

Transcript identifiers

Ensembl transcripts: 35 — 18 protein_coding, 12 retained_intron, 5 nonsense_mediated_decay

ENST00000354464, ENST00000557996, ENST00000558046, ENST00000558193, ENST00000558233, ENST00000558718, ENST00000558780, ENST00000559253, ENST00000559588, ENST00000559635, ENST00000560155, ENST00000560222, ENST00000560315, ENST00000560798, ENST00000560935, ENST00000561034, ENST00000561090, ENST00000561199, ENST00000561379, ENST00000561462, ENST00000625289, ENST00000885198, ENST00000885199, ENST00000885200, ENST00000885201, ENST00000885202, ENST00000885203, ENST00000919711, ENST00000919712, ENST00000919713, ENST00000919714, ENST00000919716, ENST00000919717, ENST00000945449, ENST00000945450

RefSeq mRNA: 1 — MANE Select: NM_024658 NM_024658

CCDS: CCDS9616

Canonical transcript exons

ENST00000354464 — 30 exons

Exon	Start	End
ENSE00001508611	24188719	24188816
ENSE00003466138	24185861	24185970
ENSE00003506357	24185459	24185567
ENSE00003507316	24183456	24183513
ENSE00003510671	24181955	24182163
ENSE00003520597	24186708	24186791
ENSE00003526867	24184298	24184418
ENSE00003528231	24183250	24183355
ENSE00003547723	24183590	24183667
ENSE00003548706	24182792	24182842
ENSE00003550362	24180219	24180572
ENSE00003552295	24186129	24186182
ENSE00003555373	24187400	24187579
ENSE00003564657	24184867	24184980
ENSE00003577366	24186878	24186979
ENSE00003579813	24182278	24182403
ENSE00003613267	24183783	24183898
ENSE00003627012	24180689	24180758
ENSE00003636011	24183998	24184109
ENSE00003638228	24187085	24187150
ENSE00003643838	24184650	24184763
ENSE00003657129	24187667	24187796
ENSE00003663909	24181711	24181843
ENSE00003669275	24181513	24181617
ENSE00003670015	24182976	24183169
ENSE00003670720	24186287	24186451
ENSE00003690039	24185183	24185312
ENSE00003804391	24188216	24188257
ENSE00003804965	24188552	24188638
ENSE00003808412	24188344	24188423

Expression profiles

Bgee: expression breadth ubiquitous, 134 present calls, max score 94.98.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 50.4141 / max 312.7597, expressed in 1809 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
142543	49.2177	1809
142544	1.0363	653
142542	0.1600	64

Top tissues by expression

134 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
left testis	UBERON:0004533	94.98	gold quality
right testis	UBERON:0004534	94.84	gold quality
testis	UBERON:0000473	93.85	gold quality
body of pancreas	UBERON:0001150	91.32	gold quality
gastrocnemius	UBERON:0001388	89.95	gold quality
right uterine tube	UBERON:0001302	89.66	gold quality
muscle of leg	UBERON:0001383	89.10	gold quality
pancreas	UBERON:0001264	88.73	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	88.68	gold quality
right adrenal gland	UBERON:0001233	88.62	gold quality
hindlimb stylopod muscle	UBERON:0004252	88.49	gold quality
sural nerve	UBERON:0015488	88.40	gold quality
adenohypophysis	UBERON:0002196	88.23	gold quality
right adrenal gland cortex	UBERON:0035827	88.22	gold quality
pituitary gland	UBERON:0000007	88.00	gold quality
left adrenal gland	UBERON:0001234	87.82	gold quality
left adrenal gland cortex	UBERON:0035825	87.65	gold quality
adult mammalian kidney	UBERON:0000082	87.27	gold quality
adrenal gland	UBERON:0002369	87.09	gold quality
metanephros cortex	UBERON:0010533	87.06	gold quality
skeletal muscle tissue	UBERON:0001134	86.95	gold quality
esophagus mucosa	UBERON:0002469	86.93	gold quality
fallopian tube	UBERON:0003889	86.53	gold quality
bone marrow cell	CL:0002092	86.50	gold quality
right lobe of thyroid gland	UBERON:0001119	86.37	gold quality
cortex of kidney	UBERON:0001225	86.14	gold quality
left uterine tube	UBERON:0001303	85.91	gold quality
bone marrow	UBERON:0002371	85.83	gold quality
mucosa of transverse colon	UBERON:0004991	85.83	gold quality
kidney	UBERON:0002113	85.81	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	2.83

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

16 targeting IPO4, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-144-3P	99.94	73.98	2698
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-3140-3P	99.88	68.47	2069
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-556-3P	99.74	68.75	1203
HSA-MIR-3714	99.71	70.74	2671
HSA-MIR-4506	99.34	67.47	526
HSA-MIR-10399-5P	99.17	69.87	2610
HSA-MIR-6504-3P	99.17	69.31	2891
HSA-MIR-194-5P	99.01	69.65	1465
HSA-MIR-4656	98.79	66.22	1306
HSA-MIR-1910-3P	98.44	67.51	1695
HSA-MIR-6511A-5P	98.13	67.47	1770
HSA-MIR-219B-5P	97.91	65.80	531

Literature-anchored findings (GeneRIF, showing 8)

• demonstrated that vitamin D receptor (VDR) has two nuclear import systems: ligand-dependent & ligand-independent pathways, & that importin 4 fulfills the ligand-independent nuclear transport through the interaction with the amino terminus of VDR (PMID:16207705)
• importins 4 and 7 accomplish nuclear import of HIF-1alpha more efficiently than the classical importin alpha/beta NLS receptor. (PMID:19788888)
• report a function of IPO4 and nuclear import in the Fanconi anemia pathway of DNA repair (PMID:20805509)
• Importins, Impbeta, Kapbeta2, Imp4, Imp5, Imp7, Imp9, and Impalpha, show the H3 tail binding more tightly than the H4 tail. The H3 tail binds Kapbeta2 and Imp5 with KD values of 77 and 57 nm, respectively, and binds the other five Importins more weakly. (PMID:27528606)
• Study identified a core region encompassing nt - 118 to + 108 of IPO4 gene that is necessary for its promoter activity. Transcription factors binding to this region were screened, resulting in the identification of two members of the Ets family, Ets-like transcription factor-1 and GA binding protein, which repress or activate its promoter activity, respectively. (PMID:28254634)
• Importin-4 functions as a driving force in human primary gastric cancer. (PMID:30861176)
• Inhibiting Importin 4-mediated nuclear import of CEBPD enhances chemosensitivity by repression of PRKDC-driven DNA damage repair in cervical cancer. (PMID:32661323)
• Nucleoporin Nup98 is an essential factor for ipo4 dependent protein import. (PMID:38780165)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	ipo4	ENSDARG00000041493
mus_musculus	Ipo4	ENSMUSG00000002319
rattus_norvegicus	Ipo4	ENSRNOG00000019553
drosophila_melanogaster	Arts	FBGN0042177
drosophila_melanogaster	Apl	FBGN0042178

Paralogs (5): IPO5 (ENSG00000065150), TNPO1 (ENSG00000083312), TNPO2 (ENSG00000105576), KPNB1 (ENSG00000108424), RANBP6 (ENSG00000137040)

Protein

Protein identifiers

Importin-4 — Q8TEX9 (reviewed: Q8TEX9)

Alternative names: Importin-4b, Ran-binding protein 4

All UniProt accessions (8): Q8TEX9, H0YK93, H0YKG5, H0YL92, H0YLV0, H0YMR4, H0YN07, H0YN14

UniProt curated annotations — full annotation on UniProt →

Function. Nuclear transport receptor that mediates nuclear import of proteins, such as histones, RPS3A, TNP2 and VDR. Serves as receptor for nuclear localization signals (NLS) in cargo substrates. Is thought to mediate docking of the importin/substrate complex to the nuclear pore complex (NPC) through binding to nucleoporin and the complex is subsequently translocated through the pore by an energy requiring, Ran-dependent mechanism. At the nucleoplasmic side of the NPC, Ran binds to the importin, the importin/substrate complex dissociates and importin is re-exported from the nucleus to the cytoplasm where GTP hydrolysis releases Ran. The directionality of nuclear import is thought to be conferred by an asymmetric distribution of the GTP- and GDP-bound forms of Ran between the cytoplasm and nucleus. Mediates the nuclear import of the histone H3-H4 dimer when in complex with ASF1 (ASF1A or ASF1B). Also mediates the nuclear import of monomeric histones H3.1 and H4. Mediates the ligand-independent nuclear import of vitamin D receptor (VDR). In vitro, mediates the nuclear import of human cytomegalovirus UL84 by recognizing a non-classical NLS.

Subunit / interactions. Found in a cytosolic complex with ASF1 (ASF1A or ASF1B) and histones H3 and H4.

Subcellular location. Cytoplasm. Nucleus.

Similarity. Belongs to the importin beta family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q8TEX9-1	1	yes
Q8TEX9-2	2

RefSeq proteins (1): NP_078934* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001494	Importin-beta_N	Domain
IPR011989	ARM-like	Homologous_superfamily
IPR016024	ARM-type_fold	Homologous_superfamily
IPR021133	HEAT_type_2	Repeat
IPR034085	TOG	Domain
IPR040122	Importin_beta	Family
IPR057672	TPR_IPO4/5	Domain
IPR058584	IMB1_TNPO1-like_TPR	Domain

Pfam: PF03810, PF13513, PF25574, PF25780

UniProt features (105 total): helix 72, turn 10, strand 9, repeat 6, sequence variant 2, sequence conflict 2, chain 1, domain 1, modified residue 1, splice variant 1

Structure

Experimental structures (PDB)

4 structures.

PDB	Method	Resolution (Å)
5XAH	X-RAY DIFFRACTION	3
5XBK	X-RAY DIFFRACTION	3.22
7UNK	ELECTRON MICROSCOPY	3.45
8DYO	ELECTRON MICROSCOPY	7.1

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8TEX9-F1	90.05	0.74

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 1

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 356 (showing top): GSE45365_NK_CELL_VS_BCELL_DN, GOBP_RIBOSOME_BIOGENESIS, YAATNRNNNYNATT_UNKNOWN, GOBP_INTRACELLULAR_PROTEIN_TRANSPORT, PAL_PRMT5_TARGETS_UP, SHEPARD_CRASH_AND_BURN_MUTANT_UP, GOBP_MATURATION_OF_SSU_RRNA, ACEVEDO_NORMAL_TISSUE_ADJACENT_TO_LIVER_TUMOR_DN, GOBP_ESTABLISHMENT_OF_PROTEIN_LOCALIZATION_TO_ORGANELLE, GOMF_GTPASE_BINDING, USF_C, chr14q12, MONNIER_POSTRADIATION_TUMOR_ESCAPE_UP, GOBP_NUCLEAR_TRANSPORT, WEI_MYCN_TARGETS_WITH_E_BOX

GO Biological Process (4): protein import into nucleus (GO:0006606), protein localization to nucleus (GO:0034504), intracellular protein transport (GO:0006886), protein transport (GO:0015031)

GO Molecular Function (4): nuclear localization sequence binding (GO:0008139), small GTPase binding (GO:0031267), nuclear import signal receptor activity (GO:0061608), protein binding (GO:0005515)

GO Cellular Component (5): chromatin (GO:0000785), nucleus (GO:0005634), cytoplasm (GO:0005737), membrane (GO:0016020), protein-containing complex (GO:0032991)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
import into nucleus	2
intracellular protein localization	2
intracellular protein transport	1
protein localization to nucleus	1
establishment of protein localization to organelle	1
protein localization to organelle	1
protein transport	1
intracellular transport	1
transport	1
establishment of protein localization	1
signal sequence receptor activity	1
GTPase binding	1
nucleocytoplasmic carrier activity	1
binding	1
chromosome	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1
cellular_component	1

Protein interactions and networks

STRING

2492 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
IPO4	SRSF1	Q07955	853
IPO4	ASF1B	Q9NVP2	816
IPO4	ASF1A	Q9Y294	797
IPO4	NASP	P49321	771
IPO4	H3C1	P02295	759
IPO4	IPO11	Q9UI26	746
IPO4	IPO9	Q96P70	742
IPO4	IPO13	O94829	734
IPO4	IPO7	O95373	734
IPO4	XPOT	O43592	727
IPO4	CSE1L	P55060	715
IPO4	XPO1	O14980	689
IPO4	CDAN1	Q8IWY9	684
IPO4	IPO8	O15397	668
IPO4	XPO5	Q9HAV4	667

IntAct

159 interactions, top by confidence:

A	B	Type	Score
H3C1	HAT1	psi-mi:“MI:0914”(association)	0.770
MED19	MED19	psi-mi:“MI:0914”(association)	0.730
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
CFTR	ESYT2	psi-mi:“MI:0914”(association)	0.710
HTT	IPO4	psi-mi:“MI:0915”(physical association)	0.670
SCN2B	EXOC5	psi-mi:“MI:0914”(association)	0.640
ASF1B	HAT1	psi-mi:“MI:0914”(association)	0.640
ASF1A	HAT1	psi-mi:“MI:0914”(association)	0.640
FANCD2	CEBPD	psi-mi:“MI:0914”(association)	0.610
IPO4	CEBPD	psi-mi:“MI:0914”(association)	0.610
CEBPD	IPO4	psi-mi:“MI:0915”(physical association)	0.610
CEBPD	IPO4	psi-mi:“MI:0914”(association)	0.610
HGS	IPO4	psi-mi:“MI:0915”(physical association)	0.560
IPO4	TCP11L1	psi-mi:“MI:0915”(physical association)	0.560
ARRDC4	WWP2	psi-mi:“MI:0914”(association)	0.530
ODAPH	TCAF2	psi-mi:“MI:0914”(association)	0.530
NPPA	A2ML1	psi-mi:“MI:0914”(association)	0.530
ASF1A	MCM4	psi-mi:“MI:0914”(association)	0.530

BioGRID (323): IPO4 (Affinity Capture-RNA), IPO4 (Affinity Capture-RNA), IPO4 (Affinity Capture-MS), IPO4 (Affinity Capture-MS), IPO4 (Affinity Capture-MS), ATP5B (Co-fractionation), IPO4 (Co-fractionation), IPO4 (Co-fractionation), IPO4 (Co-fractionation), IPO4 (Co-fractionation), IPO4 (Co-fractionation), PSMC2 (Co-fractionation), VCP (Co-fractionation), IPO4 (Affinity Capture-MS), IPO4 (Proximity Label-MS)

ESM2 similar proteins: A0JMW2, A2VE70, A4IG72, A6QR40, A7E2Y6, A7MB11, B9EJR8, E0CZ22, E1BP36, E7FBU4, I3L5V6, O43156, O70576, O75155, Q08AM6, Q0P5H9, Q0V9L1, Q15021, Q499U2, Q5FVB0, Q5JTH9, Q5ZKD5, Q66H56, Q6AY79, Q6DCF2, Q6NXR4, Q6P5B0, Q6ZQ73, Q80W92, Q86Y56, Q8BGV4, Q8BYZ7, Q8C3I8, Q8C3S2, Q8K2Z4, Q8NDA8, Q8TEX9, Q8VI75, Q91V83, Q96BJ8

Diamond homologs: Q8TEX9, Q8VI75

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 178 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
SHC-mediated cascade:FGFR3	5	26.4×	2e-04
FCERI mediated MAPK activation	6	18.2×	2e-04
DAP12 signaling	5	16.2×	7e-04
Regulation of RAS by GAPs	6	10.2×	1e-03

GO biological processes:

GO term	Partners	Fold	FDR
nucleosome assembly	8	7.6×	7e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

289 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	238
Likely benign	7
Benign	3

Top pathogenic / likely-pathogenic (0)

SpliceAI

5092 predictions. Top by Δscore:

Variant	Effect	Δscore
14:24180684:CTCAC:C	donor_loss	1.0000
14:24180685:TCA:T	donor_loss	1.0000
14:24180688:CCT:C	donor_loss	1.0000
14:24180759:C:CC	acceptor_gain	1.0000
14:24181850:C:CT	acceptor_gain	1.0000
14:24181936:T:TA	donor_gain	1.0000
14:24181953:ACT:A	donor_gain	1.0000
14:24181954:CTC:C	donor_gain	1.0000
14:24181956:C:CA	donor_gain	1.0000
14:24182270:ACACT:A	donor_loss	1.0000
14:24182272:ACTCA:A	donor_loss	1.0000
14:24182273:C:CG	donor_loss	1.0000
14:24182274:T:TG	donor_loss	1.0000
14:24182276:A:AC	donor_gain	1.0000
14:24182276:ACTGT:A	donor_gain	1.0000
14:24182277:C:CT	donor_gain	1.0000
14:24182277:CT:C	donor_gain	1.0000
14:24182277:CTGT:C	donor_gain	1.0000
14:24182277:CTGTC:C	donor_gain	1.0000
14:24182839:CTGT:C	acceptor_gain	1.0000
14:24182971:CTCA:C	donor_loss	1.0000
14:24182974:A:AG	donor_loss	1.0000
14:24182974:ACCTT:A	donor_gain	1.0000
14:24182975:C:A	donor_loss	1.0000
14:24182975:CCTTC:C	donor_gain	1.0000
14:24182978:T:A	donor_gain	1.0000
14:24183243:T:A	donor_gain	1.0000
14:24183244:CCTCA:C	donor_loss	1.0000
14:24183245:CTCA:C	donor_loss	1.0000
14:24183246:TCA:T	donor_loss	1.0000

AlphaMissense

6950 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
14:24182372:G:T	A835D	0.995
14:24181999:G:C	F921L	0.994
14:24181999:G:T	F921L	0.994
14:24182001:A:G	F921L	0.994
14:24185463:A:G	L425P	0.994
14:24181997:C:T	G922E	0.993
14:24182129:G:T	A878E	0.991
14:24184654:G:C	S544R	0.991
14:24184654:G:T	S544R	0.991
14:24184656:T:G	S544R	0.991
14:24182373:C:G	A835P	0.990
14:24184307:C:G	R583P	0.990
14:24183618:C:G	A679P	0.989
14:24183634:C:A	K673N	0.989
14:24183634:C:G	K673N	0.989
14:24186166:G:T	A341E	0.989
14:24182123:C:T	G880E	0.988
14:24187729:A:G	W116R	0.988
14:24187729:A:T	W116R	0.988
14:24184101:A:G	L589P	0.987
14:24184108:A:C	Y587D	0.987
14:24185484:A:G	L418P	0.987
14:24187767:A:G	L103P	0.987
14:24188407:G:T	A58D	0.987
14:24188638:C:G	A24P	0.987
14:24182115:C:G	A883P	0.986
14:24182384:A:G	L831S	0.986
14:24188251:C:A	K81N	0.986
14:24188251:C:G	K81N	0.986
14:24188625:A:G	L28P	0.986

dbSNP variants (sampled 300 via entrez): RS1000071113 (14:24188974 A>C), RS1000580318 (14:24181495 T>A), RS1000645038 (14:24186527 C>T), RS1001115645 (14:24183732 T>C), RS1001631235 (14:24180429 T>C), RS1001651856 (14:24182521 G>A), RS1001962192 (14:24185860 C>T), RS1002568362 (14:24187203 G>A), RS1003225198 (14:24189891 C>A,T), RS1004505778 (14:24182615 C>T), RS1004725545 (14:24190219 G>A), RS1005330374 (14:24188749 C>G,T), RS1006454623 (14:24185559 G>A), RS1006665438 (14:24185952 C>A,G), RS1006701392 (14:24186684 G>A,C)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5724661 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 1,538 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1232461	MOLIBRESIB	2	1,538

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

3 potent at pChembl≥5 of 4 total, top 3 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
5.21	IC50	6090	nM	MOLIBRESIB
5.20	Kd	6364	nM	CHEMBL3752910
5.20	ED50	6364	nM	CHEMBL3752910

PubChem BioAssay actives

2 with measured affinity, of 10 total; 2 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
2-[(4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-N-ethylacetamide	2179018: Inhibition of IPO4 (unknown origin) incubated for 1 hr by colloidal coomassie staining based LC-MS/MS analysis	ic50	6.0900	uM
4-methyl-3-[(1-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148595: Binding affinity to human IPO4 incubated for 45 mins by Kinobead based pull down assay	kd	6.3637	uM

CTD chemical–gene interactions

63 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	decreases expression, increases expression, increases methylation, affects expression	5
bisphenol A	increases expression, affects expression, affects cotreatment, increases methylation, decreases expression (+1 more)	4
Cyclosporine	decreases expression, increases expression	3
cobaltous chloride	decreases expression	2
Acetaminophen	decreases expression	2
Estradiol	increases expression	2
Nickel	increases expression	2
Tretinoin	decreases expression	2
bisphenol F	affects cotreatment, increases methylation	1
dicrotophos	increases expression	1
pirinixic acid	affects binding, increases activity, increases expression	1
titanium dioxide	decreases expression	1
decabromobiphenyl ether	decreases expression	1
beta-lapachone	decreases expression	1
sodium arsenite	affects methylation	1
perfluorooctanoic acid	increases expression	1
ochratoxin A	increases expression	1
benzo(e)pyrene	decreases methylation	1
aflatoxin B2	decreases methylation	1
di-n-butylphosphoric acid	affects expression	1
perfluoro-n-nonanoic acid	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
ICG 001	decreases expression	1
bisphenol B	increases expression	1
2-amino-14,16-dimethyloctadecan-3-ol	decreases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	decreases expression	1
hexabrominated diphenyl ether 153	decreases expression	1
bisphenol S	increases expression	1
LDN 193189	affects cotreatment, decreases expression	1
(+)-JQ1 compound	decreases expression	1

ChEMBL screening assays

7 unique, capped per target: 7 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5651637	Binding	Binding affinity to human IPO4 incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Cellosaurus cell lines

3 cell lines: 2 cancer cell line, 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B2ZD	Abcam HEK293T IPO4 KO	Transformed cell line	Female
CVCL_E2A3	HAP1 IPO4 (-) 1	Cancer cell line	Male
CVCL_E2A4	HAP1 IPO4 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.